Systems Modeling Identifies Divergent Receptor Tyrosine Kinase Reprogramming to MAPK Pathway Inhibition
Introduction - Targeted cancer therapeutics have demonstrated more limited clinical efficacy than anticipated, due to both intrinsic and acquired drug resistance. Underlying mechanisms have been largely attributed to genetic changes, but a substantial proportion of resistance observations remain une...
Príomhchruthaitheoirí: | , , , , |
---|---|
Rannpháirtithe: | |
Formáid: | Alt |
Teanga: | English |
Foilsithe / Cruthaithe: |
Springer US
2018
|
Rochtain ar líne: | http://hdl.handle.net/1721.1/117218 https://orcid.org/0000-0003-1224-8153 https://orcid.org/0000-0001-6284-2711 https://orcid.org/0000-0002-0050-989X |